← Company directoryNASDAQ · SEC EDGAR
Theravance Biopharma, Inc.
TBPHA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
SHARE PRICE · INDICATIVE——
A recent price could not be verified. Check the exchange before trading.
ANALYSIS ROUTE
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
Anticipated Theravance Biopharma–Zymeworks merger closing
The Zymeworks merger approved by Theravance Biopharma shareholders on September 18 is expected to close on September 23, which is anticipated to be the final trading day for TBPH shares. Holders will receive $17 in cash plus one non-transferable contingent value right per share.
Nasdaq ↗Anticipated Nasdaq suspension of Theravance Biopharma trading
If the merger closes as anticipated, TBPH trading is expected to be suspended from Nasdaq effective September 24. The merger consideration is $17 in cash plus one non-transferable contingent value right per share.
Nasdaq ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
TBCHTurtle Beach CorporationNASDAQ · SEC→TBCVUThunder Bridge Capital Partners V, Ltd. - UnitsNASDAQ · SEC→TBLATaboola.com Ltd.NASDAQ · SEC→TBLDThornburg Income Builder Opportunities Trust - Closed End FundNASDAQ · SEC→TCToken Cat LimitedNASDAQ · SEC→TCBITexas Capital Bancshares, Inc.NASDAQ · SEC→TCBIOTexas Capital Bancshares, Inc.NASDAQ · SEC→TCBKTriCo BancsharesNASDAQ · SEC→
DATA STATUS
Open official filings ↗Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.